Restoring the biological activity of crizanlizumab at physiological conditions through a pH-dependent aspartic acid isomerization reaction.
Bickel F, Griaud F, Kern W, Kroener F, Gritsch M, Dayer J, Barteau S, Denefeld B, Kao-Scharf CY, Lang M, Slupska-Muanza I, Schmidt C, Berg M, Sigg J, Boado L, Chelius D.
Bickel F, et al. Among authors: boado l.
MAbs. 2023 Jan-Dec;15(1):2151075. doi: 10.1080/19420862.2022.2151075.
MAbs. 2023.
PMID: 36519228
Free PMC article.